- Global Pharma News & Resources

Bladder Cancer Therapeutics Market Trends 2020: Latest Devices, Key Players Statistics Data, Regional Business Outlook 2026

As per stats released by the World Cancer Research Fund International, around 430,000 new cases of bladder cancer were diagnosed in 2012, with bladder cancer being the ninth-most common cancer. The bladder holds urine before it leaves the body during urination. In this condition, cancerous cells are formed in the urinary bladder. There are three major types of bladder cancer and are named based on the type of cells become cancerous (malignant). These types are as follows –

Transitional Cell Carcinoma: This is the common type of bladder cancer. Transitional cell carcinoma is also called urothelial carcinoma and it begins in the urothelial cells of the bladder which are present in the lining the bladder.

Request Sample Copy of the Business Report:

Squamous Cell Carcinoma: This type of cancer initiates in the squamous cells and it develops in the bladder, which leads to prolonged irritation or infection

Adenocarcinoma: This type of cancer begins in the secretory cells (glandular) that are located in the lining of the bladder and it is a very rare type of bladder cancer.

According to the study of the American Society of Clinical Oncology (ASCO), urothelial carcinoma accounts for around 90%, squamous cell carcinoma accounts for 4% and adenocarcinoma accounts for 2% of all bladder cancer. The remaining 4% of bladder cancer includes other rare types of bladder cancer viz. sarcoma and small cell anaplastic cancer. There are different types of treatment followed by doctors, which are mostly dependent on the patient’s preference for treatment and also based on type, possible side effects of the treatment, and stage of bladder cancer.

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Bladder cancer therapeutics market taxonomy:

Global Market by Bladder Cancer Type

  • Urothelial Carcinoma
  • Squamous Cell Carcinoma
  • Adenocarcinoma

Global Market by Treatment Type

  • Surgery
    • Transurethral bladder tumor resection (TURBT)
    • Cystectomy
    • Urinary Diversion
  • Chemotherapy
    • Intravesical (local) Chemotherapy
    • Systemic (whole-body) Chemotherapy
  • Immunotherapy
    • Intravesical Therapy
    • Interferon Therapy
  • Radiation Therapy

Global Market by Test Type

  • Biopsy
  • Cystoscopy
  • Urine Cytology
  • Urinalysis
  • Bladder Ultrasound

Global Market by Gender

  • Men
  • Women

Global Market by Geography

  • North America
  • Europe
  • APAC
  • Latin America
  • Middle East
  • Africa

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @

Growing incidence rate, especially in developed regions fueling the growth of bladder cancer therapeutics market

As per stats released by the International Agency for Research on Cancer (IARC), 59% of bladder cancer cases are observed in developed countries, with Belgium reporting the highest number of bladder cancer cases. As per stats released by Cancer Research UK—a charity involved in cancer research and development—here were around 10,100 new cases reported in the U.K. in 2014. Bladder cancer accounts for around 3% of all new cancer cases reported in the U.K. As per a study by the American Society of Clinical Oncology (ASCO), the incidence rate of the disease has decreased by around 12% in the U.K. in the recent past.

According to a study by the Cancer Research Institute, bladder cancer is more prevalent among men than women. Around 77,000 new cases were diagnosed in the U.S. in 2016, leading to 16,000 deaths. Continuous advancements in clinical research resulted in an increased survival rate of people suffering from bladder cancer, which is around 77% observed in the last few years. As per the stats of the American Cancer Society, bladder cancer accounts for 5% of all new cancer cases in the U.S.

Some of the major causes of the urinary bladder are unhealthy habits, smoking, continuous exposure of industrial chemicals, drinking water with a high level of arsenic, family history of bladder cancer, and long-term use of urinary catheters. In Africa and Middle East schistosomiasis and infested water is the leading cause of bladder cancer.

North America holds a major share in the global bladder cancer therapeutics market, followed by Europe due to the availability of advanced treatments, developed economy, and easy access to advanced healthcare facilities. The market in the APAC region will witness a high growth rate in the near future, due to increasing per capita income, rising government initiatives on enhancing healthcare infrastructure, growing FDI in healthcare, and rapidly increasing the geriatric population base. As per stats released by the Department of Industrial Policy and Promotion (DIPP), the healthcare sector in India witness FDI worth US$ 4.09 billion between April 2000 and September 2016. Also, medical tourism in the region is a flourishing business, due to easy access to a high-quality low-cost treatment option. According to data released by the India Brand Equity Foundation (IBEF)— a Trust established by the Department of Commerce, Ministry of Commerce and Industry, Government of India—the medical tourism industry in India rakes in US$ 3 billion each year. This creates a highly conducive environment for the growth of the bladder cancer therapeutics market in the region.

On the downside, growing usage of generic drugs, high cost of treatment, asymptomatic nature of the disease and fewer pipeline products is expected to curb the market growth. As per data released by the American Cancer Society, only one drug received approval from the FDA in the last three decades.

To understand Research Methodology, please click

The major companies playing a key role in bladder therapeutics market are Sanofi S.A., F. Hoffmann-La Roche AG, Novartis, Pfizer, Eli Lilly and Co., GlaxoSmithKline, Bristol-Myers Squibb, Allergan Inc., AVI Biopharma Inc., and AstraZeneca plc. Some are the major drugs approved by the Food and Drug Administration used for the treatment of bladder cancer are Cisplatin, Nivolumab, Thiotepa, Atezolizumab, Doxorubicin Hydrochloride, Opdivo (Nivolumab), Platinol-AQ (Cisplatin), Platinol (Cisplatin), and Tecentriq (Atezolizumab).

Key Developments

  • Market players are involved in various business strategies such as gaining product approval from regulatory authorities, in order to expand their product portfolio and strengthen the market position. For instance, in May 2017, Merck & Co., a pharmaceutical company, received the U.S. Food and Drug Administration Approval (FDA) for Keytruda (pembrolizumab) indicated for the treatment of urothelial carcinoma or also called bladder cancer.
  • Key players in the market are focused on different growth strategies such as research and development, in order to expand their product portfolio. For instance, in August 2019, Roche Holding AG, a Swiss healthcare company, announced the positive results for Tecentriq (atezolizumab), which meets its co-primary endpoint in Phase III IMvigor 130 trial, indicated for the treatment of bladder cancer.
  • Key players in the market are involved in various growth strategies such as gaining product approval from regulatory authorities, in order to expand their product portfolio and enhance their market position. For instance, in February 2017, Bristol-Myers Squibb, a U.S.-based pharmaceutical company, received the U.S. FDA approval for Opdivo (nivolumab) injection for intravenous use, which is indicated for the treatment of urothelial carcinoma or bladder cancer.

Table of Content

Global Bladder Cancer Therapeutics Market Research Report
Section 1: Global Bladder Cancer Therapeutics Industry Overview
Section 2: Global Economic Impact on Bladder Cancer Therapeutics Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Bladder Cancer Therapeutics Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Bladder Cancer Therapeutics Market Forecast

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 02-Mar-2021